Neurotoxicity
The advent of ifosfamide-related encephalopathy is unpredictable
Published in Cancer Weekly, June 29th, 2004
"This retrospective trial was performed to determine risk factors, incidence and severity of ifosfamide-induced encephalopathy in correlation with patient and treatment characteristics. Patients receiving ifosfamide were included consecutively with no restrictions concerning disease, prior chemotherapy or disease stage. Incidence and severity of encephalopathy were graduated according to common toxicity criteria," researchers in Germany report.
"Between July 2001 and July 2002, 60 patients (32 male, 28 female, median age 47.5 years) were included; 26.6% of the patients (n=16) developed...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2004-06-29)
More Articles from Cancer Weekly
- Acute myeloid leukemia
Fusion proteins overcome the hurdle of leukemia cell chemoresistance - Cancer Prognosis
Calcitonin gene hypermethylation marks the progress of leukemia - Chemotherapy
Oral RDP58 permits CPT-11 dose escalation and relieves gastric tract toxicity - Diagnostics
Human urine contains colorectal cancer detection markers - Fibrinolysis
Plasma D-dimer identifies lymph node metastasis in breast cancer patients - Acute Lymphoblastic Leukemia
Family having hematopoietic cancers poses slight risk of offspring getting ALL - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
